On May 7, 2019 Medivir AB (Nasdaq Stockholm: MVIR) reported that data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma patients, will be presented during the 2019 Society for Investigative Dermatology (SID) annual meeting in Chicago, USA (Press release, Medivir, MAY 7, 2019, View Source [SID1234535776]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data will be presented on a poster and orally on May 10 and 11, respectively. The title of the abstract is: "An Open-Label Phase 2 Clinical Trial of Topical Remetinostat Gel for Basal Cell Carcinoma".

Authors: Nicole Urman B.S., Shaundra Eichstadt M.D., Hanh Do B.S., Amar Mirza B.S., Irene Bailey Ph.D., Shufeng Li Ph.D., Stanley T. Hollmig, Jean Y. Tang M.D. Ph.D., Anthony E. Oro M.D. Ph.D., Sumaira Aasi M.D., and Kavita Y. Sarin M.D. Ph.D.

Details of all presentations for the 2019 SID annual meeting are available at the conference website:View Source

For further information, please contact:
Uli Hacksell, CEO, Medivir AB, phone: +46(0)73-125-0615